TrialCancer science2020

A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.

Masatoshi Kudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.